Image

The Sarcoma Biology and Outcome Project

The Sarcoma Biology and Outcome Project

Recruiting
12 years and older
All
Phase N/A

Powered by AI

Overview

SarcBOP - An interdisciplinary and translational registry

SarcBOP aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research. SarcBOP thus will not be limited to specific questions or patient groups, but instead will build a comprehensive database including clinical, pathologic, and radiologic information, multi-layered molecular data, and patient-reported outcomes, combined with a dedicated biobank for tissue samples and liquid biopsies. As the study integrates seamlessly with the clinical activities of the Heidelberg Sarcoma Center, the Molecular Diagnostics Program of NCT Heidelberg, including the NCT/DKTK MASTER Program, and with the NCT Trial Center, including the PMO Clinical Trials Program, SarcBOP will generate a comprehensive and continuously growing resource for clinicians, researchers, and, finally, patients.

Description

The following data are collected and stored:

  • Demographics
  • Comorbidities
  • Clinical characteristics at diagnosis, relapse and progression
  • Radiologic images
  • Histological images
  • Treatments including DRG and OPS data, including detailed information on surgical, radiation, and medical therapy as well as treatment relevant follow-up data
  • Longitudinal disease assessments
  • Clinical outcome
  • Genomic, transcriptomic, epigenomic and proteomic data
  • Patient reported outcomes

Furthermore, biological samples are collected and processed by the Sample Processing Laboratory of the Heidelberg Center for Personalized Oncology and the NCT Biobank.

Eligibility

Inclusion Criteria:

  • Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS)
  • Age ≥12 years
  • Ability to understand nature and individual consequences of the registry
  • Written informed consent
  • Subjects who are physically or mentally capable of giving consent

Exclusion Criteria:

        • Severe neurological or psychiatric disorder interfering with the ability to give written
        informed consent

Study details
    Sarcoma
    Malignant Mesenchymoma
    Sarcoma of Bone and Connective Tissue

NCT04758325

Prof. Dr. Richard F Schlenk

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.